<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1" /><br>Title: Applying More Formalized Approaches to Drug Risk-benefit Assessments</br><br>Author: Theresa Mullin, Theresa.Mullin@fda.hhs.gov</br><br>Year: 2008</br><br>Abstract: FDA risk-benefit assessment includes safety and effectiveness data for a specified drug, findings for other drugs for the same indication, and other factors, using quantitative analysis as well as subjective weighing of evidence.  Some have recommended FDA adopt formalized multi-attribute approaches; FDA is interested in exploring the potential applicability and limitations. This talk will describe candidate case studies where more formalized methods might be helpful and criteria for evaluation.</br>